Praxis Precision Medicines, Inc.(PRAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PRAX Praxis Precision Medicines, Inc.

Post-Mkt 02-10 19:39:37 EST

320.48

+0.94

+0.29%

盘后320.29

-0.19-0.06%

18:57 EST

High326.88	Low315.42	Vol348.64K
Open325.40	D1 Closing319.54	Amplitude3.59%
Mkt Cap8.78B	Tradable Cap7.35B	Total Shares27.41M
T/O111.93M	T/O Rate1.52%	Tradable Shares22.92M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PRAX","market":"US","secType":"STK","nameCN":"Praxis Precision Medicines, Inc.","latestPrice":320.48,"timestamp":1770757200000,"preClose":319.54,"halted":0,"volume":348642,"hourTrading":{"tag":"盘后","latestPrice":320.29,"preClose":320.48,"latestTime":"18:57 EST","volume":7431,"amount":2381554.27917,"timestamp":1770767862327,"change":-0.19,"changeRate":-0.000593,"amplitude":0.020032},"delay":0,"changeRate":0.0029417287350566364,"floatShares":22922500,"shares":27407100,"eps":-12.922727,"marketStatus":"Post-Mkt","change":0.94,"latestTime":"02-10 19:39:37 EST","open":325.4,"high":326.88,"low":315.42,"amount":111934777.38912001,"amplitude":0.035864,"askPrice":326.95,"askSize":2,"bidPrice":320,"bidSize":20,"shortable":3,"etf":0,"ttmEps":-12.922727,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1770771600000},"marketStatusCode":4,"adr":0,"listingDate":1602820800000,"exchange":"NASDAQ","adjPreClose":319.54,"preHourTrading":{"tag":"盘前","latestPrice":325,"preClose":319.54,"latestTime":"09:25 EST","volume":6957,"amount":2234250.2898000004,"timestamp":1770733500019,"change":5.46,"changeRate":0.017087,"amplitude":0.029511},"postHourTrading":{"tag":"盘后","latestPrice":320.29,"preClose":320.48,"latestTime":"18:57 EST","volume":7431,"amount":2381554.27917,"timestamp":1770767862327,"change":-0.19,"changeRate":-0.000593,"amplitude":0.020032},"volumeRatio":0.706493,"impliedVol":0.8899,"impliedVolPercentile":0.4422},"requestUrl":"/m/hq/s/PRAX/tweets","defaultTab":"tweets","newsList":[{"id":"2610671466","title":"Praxis Precision Medicines Updates Non-Employee Director Compensation Policy","url":"https://stock-news.laohu8.com/highlight/detail?id=2610671466","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610671466?lang=en_us&edition=fundamental","pubTime":"2026-02-11 05:53","pubTimestamp":1770760403,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines Inc. has issued an amendment to its Non-Employee Director Compensation Policy, effective February 6, 2026. The updated policy outlines the compensation structure for outside directors, including quarterly cash retainers and details regarding payment terms and definitions. The amendment supersedes any prior compensation policies for non-employee directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 10, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDL20SWQJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","IE00BJJMRZ35.SGD","PRAX","LU0109394709.USD","BK4139","IE0002141913.USD","IE00B4R5TH58.HKD","LU0889565916.HKD","IE00B2B36J28.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2610933626","title":"Praxis Precision Med Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2610933626","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610933626?lang=en_us&edition=fundamental","pubTime":"2026-02-10 22:21","pubTimestamp":1770733260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 10, 2026 09:21 ET (14:21 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","LU0889565916.HKD","IE00BJJMRZ35.SGD","LU0320765992.SGD","BK4139","IE00B2B36J28.USD","IE0009355771.USD","IE00BJT1NW94.SGD","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0109394709.USD","PRAX"],"gpt_icon":0},{"id":"2610263665","title":"Praxis Precision Medicines Inc. published an update to their financial calendar","url":"https://stock-news.laohu8.com/highlight/detail?id=2610263665","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610263665?lang=en_us&edition=fundamental","pubTime":"2026-02-10 05:01","pubTimestamp":1770670871,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines Inc. will report its fourth quarter and full year 2025 financial results and provide a corporate update before the financial markets open on Thursday, February 19, 2026. The company will host a conference call and live webcast to review the results and provide an update at 8:00 am ET on the same day. The webcast can be accessed by visiting this registration link. Replays will be available on Praxis' Events & Presentations page of the company's website for approximately 90 days. Praxis management will attend the call.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief via GlobeNewswire  on February 09, 2026, and is sole","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nNDL6m0w1d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BGHQF748.EUR","IE00B2B36J28.USD","BK4588","LU2210149790.SGD","LU2095319765.USD","SG9999014013.SGD","BK4585","BK4139","BK4112","IE00B3QW5Z07.USD","LU0320765992.SGD","LU2210150020.SGD","IE00BKPKM429.USD","LU0314104364.USD","IE00BJJMRZ35.SGD","PRAX","SG9999014021.USD","IE00BFTCPJ56.SGD","IE0002141913.USD","IE00B4R5TH58.HKD","LU0109394709.USD","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BJT1NW94.SGD","NDAQ","LU0889565916.HKD","IE0009355771.USD"],"gpt_icon":0},{"id":"2610661805","title":"Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2610661805","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610661805?lang=en_us&edition=fundamental","pubTime":"2026-02-10 05:01","pubTimestamp":1770670860,"startTime":"0","endTime":"0","summary":"857-702-9452. Media Contact:. Dan Ferry. LifeSci Advisors. 617-430-7576","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/09/3234882/0/en/Praxis-Precision-Medicines-to-Report-Fourth-Quarter-and-Full-Year-2025-Financial-Results-on-Thursday-February-19-2026-and-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","LU0109394709.USD","BK4561","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BK4200","LU0889565916.HKD","ASO","CNS","IE00B4R5TH58.HKD","PRAX","LU0320765992.SGD","BK4135","IE00B2B36J28.USD","BK4139","IE0009355771.USD"],"gpt_icon":0},{"id":"2610532986","title":"Exploring 3 High Growth Tech Stocks In The US Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2610532986","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610532986?lang=en_us&edition=fundamental","pubTime":"2026-02-09 19:08","pubTimestamp":1770635307,"startTime":"0","endTime":"0","summary":"As February begins, the U.S. stock market has shown a robust start with major indices like the Dow Jones and S&P 500 posting significant gains, reflecting positive sentiment despite recent economic uncertainties such as delayed jobs reports and trade policy shifts. In this dynamic environment, high growth tech stocks are often characterized by their innovative capabilities and potential to leverage emerging trends like AI and cloud computing, making them intriguing options for investors...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/8041000-choice1-main-header/1585186668959","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8041000-choice1-main-header/1585186668959"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/software/nyse-bill/bill-holdings/news/exploring-3-high-growth-tech-stocks-in-the-us-market-63","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/software/nyse-bill/bill-holdings/news/exploring-3-high-growth-tech-stocks-in-the-us-market-63","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4535","PRAX","BK4585","BK4139","LU0320765992.SGD","PTGX","IE00BJT1NW94.SGD","BK4023","IE0002141913.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","BK4588","BK4551","IE0009355771.USD","LU0109394709.USD","IE00B4R5TH58.HKD","LU0889565916.HKD","BILL","BILL.AU"],"gpt_icon":0},{"id":"2609390026","title":"Praxis Precision Medicines Grants Restricted Stock Units to New Employees Under 2024 Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2609390026","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609390026?lang=en_us&edition=fundamental","pubTime":"2026-02-05 05:01","pubTimestamp":1770238875,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines Inc. announced that its Compensation Committee has granted restricted stock unit awards totaling 2,964 shares of common stock to eight new non-executive employees under its 2024 Inducement Plan. The awards will vest in four equal annual installments, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief via GlobeNewswire  on February 04, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL1C2jmW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","IE00B3QW5Z07.USD","PRAX","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU0314104364.USD","LU0889565916.HKD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","BK4139","LU2210150020.SGD","NDAQ","IE00BJJMRZ35.SGD","SG9999014039.USD","LU2210149790.SGD","LU0109394709.USD","LU2095319765.USD","BK4112","IE0009355771.USD","LU0320765992.SGD","BK4585","BK4588","SG9999014021.USD","SG9999014005.SGD","SG9999014013.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2609318329","title":"Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2609318329","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609318329?lang=en_us&edition=fundamental","pubTime":"2026-02-05 05:01","pubTimestamp":1770238860,"startTime":"0","endTime":"0","summary":"Investor Contact:. 857-702-9452. Media Contact:. Dan Ferry. Life Science Advisors. 617-430-7576","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/04/3232451/0/en/Praxis-Precision-Medicines-Inc-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0320765992.SGD","BK4139","LU0889565916.HKD","BK4135","BK4200","IE0009355771.USD","CNS","IE00BFTCPJ56.SGD","BK4561","PRAX","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","ASO","IE0002141913.USD"],"gpt_icon":0},{"id":"2608363470","title":"Praxis Precision Med Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2608363470","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608363470?lang=en_us&edition=fundamental","pubTime":"2026-02-04 19:38","pubTimestamp":1770205080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 04, 2026 06:38 ET (11:38 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","PRAX","LU0109394709.USD","LU0320765992.SGD","IE00B2B36J28.USD","BK4139","IE00B4R5TH58.HKD","IE0009355771.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2608363843","title":"Needham Upside Case: Strong Ulixacaltamide Outlook and 2026 Catalyst Stack Drive Praxis Buy Thesis","url":"https://stock-news.laohu8.com/highlight/detail?id=2608363843","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608363843?lang=en_us&edition=fundamental","pubTime":"2026-02-04 19:07","pubTimestamp":1770203263,"startTime":"0","endTime":"0","summary":"In a report released today, Ami Fadia from Needham maintained a Buy rating on Praxis Precision Medicines, with a price target of $510.00. Ami Fadia...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/needham-upside-case-strong-ulixacaltamide-outlook-and-2026-catalyst-stack-drive-praxis-buy-thesis-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/needham-upside-case-strong-ulixacaltamide-outlook-and-2026-catalyst-stack-drive-praxis-buy-thesis-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B4R5TH58.HKD","PRAX","LU0320765992.SGD","IE0002141913.USD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU0889565916.HKD","IE00BFTCPJ56.SGD","BK4139","LU0109394709.USD","IE0009355771.USD","IE00B2B36J28.USD"],"gpt_icon":0},{"id":"2608860498","title":"Praxis Precision Med Initiated at Equal-Weight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2608860498","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608860498?lang=en_us&edition=fundamental","pubTime":"2026-02-02 22:55","pubTimestamp":1770044100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 02, 2026 09:55 ET (14:55 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0683600562.USD","IE00BJT1NW94.SGD","LU0971096721.USD","LU0640476718.USD","LU1201861249.SGD","IE0009355771.USD","LU0106831901.USD","LU1267930573.SGD","IE00B4R5TH58.HKD","LU0314106906.USD","LU0868494617.USD","LU0048573561.USD","IE0002141913.USD","LU0477156953.USD","LU0208291251.USD","LU1506573853.SGD","LU2461242641.AUD","LU0310800379.SGD","LU0320765992.SGD","LU2361044865.SGD","LU0154236417.USD","BK4501","IE00BJJMRZ35.SGD","LU2236285917.USD","LU1074936037.SGD","LU0310799852.SGD","LU1668664300.SGD","LU0130102774.USD","LU1363072403.SGD","BK4585","LU0070302665.USD","BK4559","LU0708994859.HKD","IE00B19Z3581.USD","LU0889565916.HKD","LU0868494708.USD","LU0289960550.SGD","IE00B7SZLL34.SGD","LU0251131958.USD","LU1069347547.HKD","BK4588","LU0320765489.SGD","IE00BFTCPJ56.SGD","LU0267386448.USD","PRAX","LU1035773651.USD","LU0072461881.USD","LU2361044949.HKD","LU0211327993.USD","LU0029864427.USD"],"gpt_icon":0},{"id":"2608869531","title":"Wells Fargo Initiates Coverage on Praxis Precision Medicines With Equal Weight Rating, $282 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2608869531","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608869531?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:36","pubTimestamp":1770035792,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines (PRAX) has an average rating of Buy and mean price target of $567.25, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fr","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PRAX"],"gpt_icon":0},{"id":"2607902549","title":"Praxis Precision Med Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2607902549","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607902549?lang=en_us&edition=fundamental","pubTime":"2026-01-31 02:58","pubTimestamp":1769799480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 30, 2026 13:58 ET (18:58 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX","LU0889565916.HKD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU0109394709.USD","BK4139","IE00BJJMRZ35.SGD","LU0320765992.SGD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","IE0002141913.USD","IE0009355771.USD"],"gpt_icon":0},{"id":"2607015084","title":"Praxis Precision Medicines Inc : TD Cowen Raises Target Price to $554 From $353","url":"https://stock-news.laohu8.com/highlight/detail?id=2607015084","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607015084?lang=en_us&edition=fundamental","pubTime":"2026-01-29 20:29","pubTimestamp":1769689771,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nFWN3YU0XT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0320765992.SGD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","IE0002141913.USD","LU0109394709.USD","PRAX","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU0889565916.HKD","BK4139","IE00BJJMRZ35.SGD","IE0009355771.USD"],"gpt_icon":0},{"id":"2607084265","title":"TD Cowen Remains a Buy on Praxis Precision Medicines (PRAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2607084265","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607084265?lang=en_us&edition=fundamental","pubTime":"2026-01-29 20:16","pubTimestamp":1769689015,"startTime":"0","endTime":"0","summary":"In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Praxis Precision Medicines, with a price target of $554.00. Baral c...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-remains-a-buy-on-praxis-precision-medicines-prax-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-remains-a-buy-on-praxis-precision-medicines-prax-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","BK4585","COWN","IE00B4R5TH58.HKD","PRAX","BK4566","IE00BJJMRZ35.SGD","IE0002141913.USD","IE00BJT1NW94.SGD","TD","IE00BFTCPJ56.SGD","LU0109394709.USD","BK4139","LU0320765992.SGD","BK4207","BK4127","IE0009355771.USD","IE00B2B36J28.USD"],"gpt_icon":0},{"id":"2606712741","title":"Praxis Precision Med Is Maintained at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2606712741","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606712741?lang=en_us&edition=fundamental","pubTime":"2026-01-28 22:16","pubTimestamp":1769609760,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 28, 2026 09:16 ET (14:16 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","LU0109394709.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BK4139","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","PRAX","LU0320765992.SGD","LU0889565916.HKD","IE0009355771.USD","IE0002141913.USD"],"gpt_icon":0},{"id":"2603581716","title":"Praxis Precision Medicines Appoints Dr. Orrin Devinsky as Head of Clinical Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2603581716","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603581716?lang=en_us&edition=fundamental","pubTime":"2026-01-14 05:30","pubTimestamp":1768339820,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines Inc. has appointed Dr. Orrin Devinsky as Head of Clinical Strategy, a newly created leadership role. Dr. Devinsky, a prominent neurologist and epilepsy expert, will guide clinical strategy and global medical affairs as the company advances its CNS medicine portfolio. He will report to Steven Petrou, President of Research and Development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief via GlobeNewswire  on January 13, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL91DBXy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BKPKM429.USD","LU0314104364.USD","LU2210150020.SGD","PRAX","BK4588","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","SG9999014005.SGD","IE0009355771.USD","LU0109394709.USD","SG9999014021.USD","IE00B2B36J28.USD","SG9999014013.SGD","IE00BJJMRZ35.SGD","LU2210149790.SGD","BK4112","SG9999014039.USD","BK4585","BK4139","NDAQ","IE0002141913.USD","IE00BGHQF748.EUR","LU0889565916.HKD","LU0320765992.SGD","IE00B4R5TH58.HKD","IE00B3QW5Z07.USD","LU2095319765.USD"],"gpt_icon":0},{"id":"2603465819","title":"Praxis Precision Medicines Appoints Global Epilepsy Leader DR. Orrin Devinsky as Head of Clinical Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2603465819","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603465819?lang=en_us&edition=fundamental","pubTime":"2026-01-14 05:30","pubTimestamp":1768339802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUA8SGB4X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE0002141913.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","PRAX","LU0109394709.USD","LU0320765992.SGD","IE00B2B36J28.USD","BK4139","IE00B4R5TH58.HKD","IE0009355771.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2603524896","title":"Praxis Precision Medicines Inc. Files Initial Statement of Beneficial Ownership for Director Jeffrey B. Kindler","url":"https://stock-news.laohu8.com/highlight/detail?id=2603524896","media":"Reuters","labels":["executive","shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603524896?lang=en_us&edition=fundamental","pubTime":"2026-01-13 06:45","pubTimestamp":1768257909,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Jeffrey B. Kindler as a director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL9Qz7fj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Praxis Precision Medicines Inc. Files Initial Statement of Beneficial Ownership for Director Jeffrey B. Kindler","news_tag":"executive,shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0889565916.HKD","IE0002141913.USD","IE00BJT1NW94.SGD","LU0109394709.USD","IE0009355771.USD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","PRAX","LU0320765992.SGD"],"gpt_icon":0},{"id":"2602545146","title":"Praxis Precision price target raised to $95 from $83 at Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2602545146","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602545146?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:13","pubTimestamp":1768227195,"startTime":"0","endTime":"0","summary":"Wedbush analyst Laura Chico raised the firm’s price target on Praxis Precision (PRAX) to $95 from $83 and keeps an Underperform rating on the share...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/praxis-precision-price-target-raised-to-95-from-83-at-wedbush-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/praxis-precision-price-target-raised-to-95-from-83-at-wedbush-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B4R5TH58.HKD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","IE0009355771.USD","BK4139","IE00BFTCPJ56.SGD","LU0109394709.USD","PRAX","IE00BJJMRZ35.SGD","LU0889565916.HKD","IE0002141913.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2602028543","title":"Praxis Precision Med Is Maintained at Underperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2602028543","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602028543?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:02","pubTimestamp":1768226520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 12, 2026 09:02 ET (14:02 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","IE0009355771.USD","BK4139","IE00BFTCPJ56.SGD","LU0109394709.USD","PRAX","IE00BJJMRZ35.SGD","LU0889565916.HKD","IE0002141913.USD","LU0320765992.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.praxismedicines.com","stockEarnings":[{"period":"1week","weight":0.0337},{"period":"1month","weight":0.1078},{"period":"3month","weight":0.7408},{"period":"6month","weight":5.5146},{"period":"1year","weight":2.6779},{"period":"ytd","weight":0.0841}],"compareEarnings":[{"period":"1week","weight":-0.0021},{"period":"1month","weight":-0.0002},{"period":"3month","weight":0.016},{"period":"6month","weight":0.0761},{"period":"1year","weight":0.1551},{"period":"ytd","weight":0.0176}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase IIb clinical trial for the treatment of essential tremor, as well as in Phase II clinical trial to treat Parkinson's disease; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.298328},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.175684},{"month":3,"riseRate":0.2,"avgChangeRate":-0.183614},{"month":4,"riseRate":0.2,"avgChangeRate":-0.018417},{"month":5,"riseRate":0.4,"avgChangeRate":-0.124101},{"month":6,"riseRate":0.4,"avgChangeRate":-0.094382},{"month":7,"riseRate":0.6,"avgChangeRate":0.167978},{"month":8,"riseRate":0.4,"avgChangeRate":0.080633},{"month":9,"riseRate":0.6,"avgChangeRate":0.013557},{"month":10,"riseRate":0.6,"avgChangeRate":0.512334},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073478},{"month":12,"riseRate":0.833333,"avgChangeRate":0.206625}],"exchange":"NASDAQ","name":"Praxis Precision Medicines, Inc.","nameEN":"Praxis Precision Medicines, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Praxis Precision Medicines, Inc.(PRAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Praxis Precision Medicines, Inc.(PRAX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Praxis Precision Medicines, Inc.,PRAX,Praxis Precision Medicines, Inc.股票,Praxis Precision Medicines, Inc.股票老虎,Praxis Precision Medicines, Inc.股票老虎国际,Praxis Precision Medicines, Inc.行情,Praxis Precision Medicines, Inc.股票行情,Praxis Precision Medicines, Inc.股价,Praxis Precision Medicines, Inc.股市,Praxis Precision Medicines, Inc.股票价格,Praxis Precision Medicines, Inc.股票交易,Praxis Precision Medicines, Inc.股票购买,Praxis Precision Medicines, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Praxis Precision Medicines, Inc.(PRAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Praxis Precision Medicines, Inc.(PRAX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}